A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes
International Journal of Hematology · 2025
DOI: 10.1007/s12185-024-03872-3 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Hiroshi Kosugi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ogaki Municipal Hospital, 4-86, Minaminokawacho, Ogaki, 503-8502, Japan. hkosugi@med.nagoya-u.ac.jp. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Recombinant Fusion Proteins, Immunoglobulin Fc Fragments, Activin Receptors, Type II. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Luspatercept has shown durable clinical efficacy for the treatment of anemia in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS). We report the results of a prespecified primary analysis of a phase 2 trial of luspatercept in non-transfusion-dependent (NTD) Japanese patients with anemia due to LR-MDS. Luspatercept (starting dose 1.0 mg/kg) was administered subcutaneously once every 3 weeks. The primary endpoint was the proportion of patients who achieved hematological improvement-erythroid (HI-E) response (≥ 1.5 g/dL increase in hemoglobin level for 8 weeks) without transfusions within the first 24 weeks of treatment. At the primary analysis data cutoff, 21 patients had been enrolled/treated; 17 and 10 patients had completed 24 and 48 weeks of treatment, respectively. HI-E response occurred within 24 weeks in 10 patients (47.6%; 95% confidence interval, 25.7–70.2; P < 0.0001), which was significantly higher than the predefined threshold (10%). By week 48, HI-E response occurred in 12 patients (57.1%) and 17 patients (81.0%) remained NTD. Luspatercept was well tolerated. Three patients (14.3%) had grade 3–4 treatment-related treatment-emergent adverse events. Luspatercept resulted in statistically and clinically significant improvements in hemoglobin levels, and may help delay the need for transfusions in NTD patients with LR-MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Ogaki Municipal Hospital, 4-86, Minaminokawacho, Ogaki, 503-8502, Japan. hkosugi@med.nagoya-u.ac.jp.
- Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
- Department of Hematology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
- Department of Internal Medicine, Hitachi General Hospital, Hitachi, Japan.
- Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
- Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Förderung
- Bristol Myers Squibb
Zitieren
APA
Kosugi, H., Fujisaki, T., Iwasaki, H., Shinagawa, A., Iida, H., Jo, T., Kubonishi, S., Morita, Y., Nakashima, Y., Onodera, K., Suzuki, K., Suzuki, T., Tamai, Y., Usuki, K., Yokota, A., Yonaga, H., Hayakawa, J., Midorikawa, S., Nishio, M., …, & Matsue, K. (2025). A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03872-3
Vancouver
Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, et al. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03872-3
BibTeX
@article{Kosugi2025,
author = {Kosugi, Hiroshi and Fujisaki, Tomoaki and Iwasaki, Hiromi and Shinagawa, Atsushi and Iida, Hiroatsu and Jo, Tatsuro and Kubonishi, Shiro and Morita, Yasuyoshi and Nakashima, Yasuhiro and Onodera, Koichi and Suzuki, Kenshi and Suzuki, Takahiro and Tamai, Yotaro and Usuki, Kensuke and Yokota, Akira and Yonaga, Hideyuki and Hayakawa, Jin and Midorikawa, Shuichi and Nishio, Mitsufumi and Suda, Makoto and Matsue, Kosei},
title = {A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes},
journal = {International Journal of Hematology},
year = {2025},
doi = {10.1007/s12185-024-03872-3}
}
EUVIMED